Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial

Blood Adv. 2024 Aug 27;8(16):4410-4413. doi: 10.1182/bloodadvances.2024013182.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Female
  • Humans
  • Leukemia, Myeloid, Acute* / therapy
  • Male
  • Neoplasm, Residual*
  • Treatment Outcome
  • Young Adult